Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

NCT06252649 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT06252649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06252649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Recruiting
Start date
July 17, 2024
Completion date
April 25, 2032
Enrollment
450 (estimated)
Sites
291

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer